HC Wainwright Reiterates Buy Rating for Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ:HALO)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $95.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 22.08% from the company’s previous close.

HALO has been the subject of a number of other research reports. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Morgan Stanley decreased their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Finally, UBS Group restated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $81.60.

Halozyme Therapeutics Trading Down 1.0%

Shares of NASDAQ:HALO opened at $77.82 on Tuesday. The company has a market capitalization of $9.23 billion, a PE ratio of 27.99, a P/E/G ratio of 0.33 and a beta of 0.84. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics has a 12-month low of $57.33 and a 12-month high of $82.26. The business’s fifty day simple moving average is $72.55 and its 200-day simple moving average is $70.43.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. During the same period in the prior year, the business posted $1.11 EPS. The firm’s quarterly revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities research analysts predict that Halozyme Therapeutics will post 7.54 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total value of $124,653.75. Following the transaction, the director directly owned 42,044 shares of the company’s stock, valued at $3,225,195.24. This represents a 3.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 1,923 shares of the firm’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $79.77, for a total value of $153,397.71. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $61,245,810.60. This trade represents a 0.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 74,102 shares of company stock valued at $5,205,798 over the last ninety days. 2.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Arrowstreet Capital Limited Partnership increased its holdings in Halozyme Therapeutics by 29.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after buying an additional 749,484 shares during the period. Dimensional Fund Advisors LP lifted its stake in Halozyme Therapeutics by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock valued at $141,613,000 after acquiring an additional 25,731 shares during the period. Norges Bank purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at $128,201,000. William Blair Investment Management LLC purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at $124,031,000. Finally, Federated Hermes Inc. increased its stake in shares of Halozyme Therapeutics by 8.5% in the fourth quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company’s stock worth $105,972,000 after acquiring an additional 123,917 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.